Long-term experience with low-dose interferon-α and PUVA in the management of early mycosis fungoides

European Journal of Haematology

Volumn 75, Issue 2, 2005, Pages 136-145

  Rupoli, Serena ^a   Goteri, Gaia ^a   Pulini, Stefano ^a   Filosa, Alessandra ^a   Tassetti, Angela ^a   Offidani, Massimo ^a   Filosa, Giorgio ^b   Mozzicafreddo, Giorgio ^c   Giacchetti, Alfredo ^c   Brandozzi, Giuliano ^a   Cataldi, Ivana ^a   Barulli, Sara ^a   Ranaldi, Renzo ^a   Scortechini, Anna Rita ^a   Capretti, Roberta ^a   Fabris, Guidalberto ^a   Leoni, Pietro ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b A Murri Hospital   (Italy)

^c INRCA   (Italy)

Author keywords

IFN ; Mycosis Fungoides; PUVA

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ELECTROLYTE; GLUCOSE; PSORALEN; UREA; URIC ACID;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CANCER REGRESSION; CANCER RELAPSE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DRUG ACTIVITY; DRUG TOLERABILITY; ELECTROLYTE BLOOD LEVEL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOSIS; MENTAL DISEASE; MULTICENTER STUDY; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUVA; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN BURNING SENSATION; SOMNOLENCE; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING;

AGED; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PUVA THERAPY; RECURRENCE; REMISSION INDUCTION; SKIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 22444448736     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00497.x     Document Type: Article

References (35)

1. KIM YH, LIU HL, MRAZ-GERNHARD S, VARGHESE A, HOPPE RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857-866.
2. HERRMANN JJ, ROENIGK HH JR, HURRIA A, KUZEL TM, SAMUELSON E, RADEMAKER AW, ROSEN ST. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995;33:234-242.
3. DIAMANDIDOU E, COHEN PR, KURZROCK R. Mycosis Fungoides and Sezary syndrome. Blood 1996;88:2385-2409.
4. JONES GW, KACINSKI BM, WILSON LD, WILLEMZE R, SPITTLE M, HOHENBERG G, HANDL-ZELLER L, TRAUTINGER F, KNOBLER R. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002;47:364-370.
5. VONDERHEID EC. Treatment of cutaneous T cell lymphoma: 2001. Recent Results Cancer Res 2002;160:309-320.
6. GATHERS RC, SCHERSCHUN L, MALICK F, FIVENSON DP, LIM HW. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol 2002;47:191-197.
7. DIEDEREN PV, VAN WEELDEN H, SANDERS CJ, TOONSTRA J, VAN VLOTEN WA. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003;48:215-219.
8. MUCHE JM, LUKOWSKY A, ASADULLAH K, GELLRICH S, STERRY W. Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood 1997;90:1636-1642.
9. ROSS C, TINGSGAARD P, JORGENSEN H, VEJLSGAARD GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 1993;51:63-72.
10. ROENIGK HH JR, KUZEL TM, SKOUTELIS AP, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990;95:198S-205S.
11. KUZEL TM, ROENIGK HH, SAMUELSON E, HERRMANN JJ, HURRIA A, RADEMAKER AW, ROSEN ST. Effectiveness of interferon alfa-2a combined with phototherapy for Mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995;13:257-263.
12. STADLER R, OTTE HG, LUGER T, HENZ BM, KUHL P, ZWINGERS T, STERRY W. Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus interferon α-2a plus PUVA in patients with cutaneous T cell lymphoma stages I and II. Blood 1998;92:3578-3581.
13. CHIARION-SILENI V, BONONI A, FORNASA CV, et al. Phase II trial of interferon-alpha-2a plus psoralen with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 2002;95:569-575.
14. RUPOLI S, BARULLI S, GUIDUCCI B, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T cell lymphoma multicenter study group. Haematologica 1999;84:809-813.
15. MOSTOW EN, NECKEL SL, OBERHELMAN L, ANDERSON TF, COOPER KD. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 1993;129:747-752.
16. BUNN PA JR, LAMBERG SI. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep 1979;63:725-728.
17. MILLER AB, HOOGSTRATEN B, STAQUET M, WINKLER A. Reporting results of cancer treatment. Cancer 1981;1:207-214.
18. ASHTON-KEY M, DISS TC, DU MQ, KIRKHAM N, WOTHERSPOON A, ISAACSON PG. The value of polymerase chain reaction in the diagnosis of cutaneous T-cell infiltrates. Am J Surg Pathol 1997;21:743-747.
19. KAPLAN EL, MEIER P. Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958;53:457-481.
20. KIM YH, MARTINEZ G, VARGHESE A, HOPPE RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol 2003;139:165-173.
21. BRENEMAN D, DUVIC M, KUZEL T, YOCUM R, TRUGLIA J, STEVENS VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-332.
22. MARTIN AG. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas. J Drugs Dermatol 2003;2:155-167.
23. KACINSKI BM, FLICK M. Apoptosis and cutaneous T cell lymphoma. Ann NY Acad Sci 2001;941:194-199.
24. DUMMER R. Immunomodulators in the treatment of cutaneous lymphomas. Expert Opin Biol Ther 2002;2:279-286.
25. MARTI RM, ESTRACH T, REVERTER JC, MASCARO JM. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991;127:1511-1516.
26. GOTERI G, FILOSA A, MANNELLO B, STRAMAZZOTTI D, RUPOLI S, LEONI P, FABRIS G. Density of neoplastic lymphoid infiltrate, CD8+ T lymphocytes and CD1a+ dendritic cells in mycosis fungoides. J Clin Pathol 2003;56:453-458.
27. LUFTL M, FENG A, LICHA E, SCHULER G. Dendritic cells and apoptosis in mycosis fungoides. Br J Dermatol 2002;147:1171-1179.
28. EDELSON RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann NY Acad Sci 2001;941:1-11.
29. MEISSNER K, MICHAELIS K, REHPENNING W, LONING T. Epidermal Langerhans' cells densities influence survival in mycosis fungoides and Sezary syndrome. Cancer 1990;65:2069-2073.
30. HOPPE RT, MEDEIROS LJ, WARNKE RA, WOOD GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995;32:448-453.
31. VERMEER MH, VAN DOORN R, DUKERS D, BEKKENK MW, MEIJER CJ, WILLEMZE R. CD8+ T cells in cutaneous T cell lymphoma: expression of cytotoxic proteins, Fas ligand and killing inhibitory receptors and their relationship with clinical behaviour. J Clin Oncol 2001;19:4322-4329.
32. DELFAU-LARUE MH, DALAC S, LEPAGE E, PETRELLA T, WECHSLER J, FARCET JP, BAGOT M. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood 1998;92:3376-3380.
33. DEREURE O, BALAVOINE M, SALLES MT, CANDON-KERLAU S, CLOT J, GUILHOU JJ, ELIAOU JF. Correlations between clinical, histologic, blood, and skin polymerase chain reaction outcome in patients treated for mycosis fungoides. J Invest Dermatol 2003;121:614-617.
34. POSZEPCZYNSKA-GUIGNE E, BAGOT M, WECHSLER J, REVUZ J, FARCET JP, DELFAU-LARUE MH. Minimal residual disease in mycosis fungoides follow-up can be assessed by polymerase chain reaction. Br J Dermatol 2003;148:265-271.
35. KLEMKE CD, DIPPEL E, DEMBINSKI A, PÖNITZ N, ASSAF C, HUMMEL M, STEIN H, GOERDT S. Clonal T cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in the skin and blood of patients with parapsoriasis and early-stage mycosis fungoides. J Pathol 2002;197:348-354.